NZ funds sneak into Aust equities
Armstrong Jones chief investment officer David McClatchy reckons that a number of New Zealand share funds are disguising their true performance by investing in Australian shares while keeping a NZSE benchmark.
McClatchy says many NZ equity funds have changed their mandates so they can invest in Australia, yet they continue to use NZSE indices as benchmarks.
"It's absolute nonsense," he says. "You can't tell whether [a manager] is doing a great job."
This creep has lead to an increasingly wider range of returns reported by so-called NZ equity funds.
It has also hit AJ's locally domiciled unit trust which continues to invest solely in New Zealand. Over the years its ranking against its peers has fallen, while the range of returns reported by NZ share funds has increased.
AJ is taking the high moral ground on this issue with the launch of its own Australasian share fund (which is an UK-based open-ended investment company managed by Edinburgh Fund Managers).
McClatchy says the fund is benchmarked against a composite index which is 50 per cent NZSE40 and 50 per cent ASX200.
The company studied various ways of developing a suitable benchmark including having one which was weighted on the relevant capitalisation of each market (such a benchmark would be heavily in Australia's favour as its market capitalisation is about A$700 billion compared to $42 billion in New Zealand).
Instead, the benchmark was worked out on what would have provided the best performance over the past 20 years.
McClatchy says their research revealed that New Zealand had marginally outperformed Australia over the last two decades.
On an unhedged basis the optimal mix was 60:40 to New Zealand. However, on a hedged basis the result was the other way around. McClatchy says that a 50:50 mix was "a prudent starting point".
Recommended for you
Global X has painted a worrying picture for active ETFs in Australia, with investor adoption proving uneven and the popularity of its low-cost index counterparts only growing stronger.
Australian equity ETFs attracted record inflows of $3.2 billion in 1Q25, while heightened volatility led to a decline in flows for global equity ETFs, according to Vanguard.
The failure of a clinical trial by biotech firm Opthea has caused shares in its backer Regal Partners to decline 52 per cent year-to-date and hit its funds under management, quarterly flows show.
GQG Partners has revealed its quarterly flows for the first three months of 2025 were up 5.8 per cent, after a difficult final quarter of 2024 as a result of institutional redemptions.
